The Effect of Esomeprazole and Fundoplication on Airways
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00994708|
Recruitment Status : Completed
First Posted : October 14, 2009
Last Update Posted : October 14, 2009
Evaluate the prevalence of bronchial responsiveness (BHR) among patients with gastroesophageal reflux disease (GERD).
Investigate correlation between bronchial reactivity and the severity of GERD, and similarly investigate the correlation between exhaled nitric oxide (NO) and the severity of GERD.
Compare the effects of esomeprazole 40 mg twice daily and Nissen fundoplication on bronchial reactivity, exhaled NO, pulmonary function and quality of life.
|Condition or disease||Intervention/treatment||Phase|
|Airway Responsiveness||Drug: esomeprazole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||The Effect of Esomeprazole and Nissen Fundoplication on Bronchial Responsiveness, Quality of Life, Exhaled Nitric Oxide and Pulmonary Function in Patients With Gastroesophageal Reflux Disease|
|Study Start Date :||December 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00994708
|Tampere University Hospital|
|Tampere, Finland, 33521|